KIR3DL1 and HLA-B density and binding calibrate NK education and response to HIV

Journal of Immunology

Volumn 196, Issue 8, 2016, Pages 3398-3410

  Boudreau, Jeanette E ^a,d   Mulrooney, Tiernan J ^a   Le Luduec, Jean Benoît ^a   Barker, Edward ^b   Hsu, Katharine C ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; HLA BW4 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 3DL1; UNCLASSIFIED DRUG; HLA-BW4 ANTIGEN; KIR3DL1 PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CELL MEMBRANE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; VIROLOGY;

CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; HIV INFECTIONS; HIV-1; HLA-B ANTIGENS; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; RECEPTORS, KIR3DL1;

EID: 84974531492     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502469     Document Type: Article

References (72)

1. Abeyweera, T. P., E. Merino, and M. Huse. 2011. Inhibitory signaling blocks activating receptor clustering and induces cytoskeletal retraction in natural killer cells. J. Cell Biol. 192: 675-690.
2. Long, E. O., H. S. Kim, D. Liu, M. E. Peterson, and S. Rajagopalan. 2013. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu. Rev. Immunol. 31: 227-258.
3. Kim, S., J. Poursine-Laurent, S. M. Truscott, L. Lybarger, Y.-J. Song, L. Yang, A. R. French, J. B. Sunwoo, S. Lemieux, T. H. Hansen, and W. M. Yokoyama. 2005. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436: 709-713.
4. Parham, P. 2005. Immunogenetics of killer cell immunoglobulin-like receptors. Mol. Immunol. 42: 459-462.
5. Anfossi, N., P. André, S. Guia, C. S. Falk, S. Roetynck, C. A. Stewart, V. Breso, C. Frassati, D. Reviron, D. Middleton, et al. 2006. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25: 331-342.
6. Ljunggren, H. G., K. Sturmhöfel, E. Wolpert, G. J. Hämmerling, and K. Kärre. 1990. Transfection of beta 2-microglobulin restores IFN-mediated protection from natural killer cell lysis in YAC-1 lymphoma variants. J. Immunol. 145: 380-386.
7. Yu, J., G. Heller, J. Chewning, S. Kim, W. M. Yokoyama, and K. C. Hsu. 2007. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J. Immunol. 179: 5977-5989.
8. Tarek, N., J.-B. Le Luduec, M. M. Gallagher, J. Zheng, J. M. Venstrom, E. Chamberlain, S. Modak, G. Heller, B. Dupont, N.-K. V. Cheung, and K. C. Hsu. 2012. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 122: 3260-3270.
9. Orr, M. T., W. J. Murphy, and L. L. Lanier. 2010. 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat. Immunol. 11: 321-327.
10. Fernandez, N. C., E. Treiner, R. E. Vance, A. M. Jamieson, S. Lemieux, and D. H. Raulet. 2005. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105: 4416-4423.
11. Hilton, H. G., L. A. Guethlein, A. Goyos, N. Nemat-Gorgani, D. A. Bushnell, P. J. Norman, and P. Parham. 2015. Polymorphic HLA-C receptors balance the functional characteristics of KIR haplotypes. J. Immunol. 195: 3160-3170.
12. Moesta, A. K., P. J. Norman, M. Yawata, N. Yawata, M. Gleimer, and P. Parham. 2008. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J. Immunol. 180: 3969-3979.
13. Carr, W. H., M. J. Pando, and P. Parham. 2005. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J. Immunol. 175: 5222-5229.
14. Yawata, M., N. Yawata, M. Draghi, A.-M. Little, F. Partheniou, and P. Parham. 2006. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 203: 633-645.
15. Norman, P. J., J. A. Hollenbach, N. Nemat-Gorgani, L. A. Guethlein, H. G. Hilton, M. J. Pando, K. A. Koram, E. M. Riley, L. Abi-Rached, and P. Parham. 2013. Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet. 9: e1003938.
16. Norman, P. J., L. Abi-Rached, K. Gendzekhadze, D. Korbel, M. Gleimer, D. Rowley, D. Bruno, C. V. F. Carrington, D. Chandanayingyong, Y.-H. Chang, et al. 2007. Unusual selection on the KIR3DL1/S1 natural killer cell receptor in Africans. Nat. Genet. 39: 1092-1099.
17. Trundley, A., H. Frebel, D. Jones, C. Chang, and J. Trowsdale. 2007. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. Eur. J. Immunol. 37: 780-787.
18. Gardiner, C. M., L. A. Guethlein, H. G. Shilling, M. Pando, W. H. Carr, R. Rajalingam, C. Vilches, and P. Parham. 2001. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J. Immunol. 166: 2992-3001.
19. Boudreau, J. E., J.-B. Le Luduec, and K. C. Hsu. 2014. Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles. PLoS One 9: e99543.
20. Gumperz, J. E., V. Litwin, J. H. Phillips, L. L. Lanier, and P. Parham. 1995. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181: 1133-1144.
21. O'Connor, G. M., J. P. Vivian, J. M. Widjaja, J. S. Bridgeman, E. Gostick, B. A. P. Lafont, S. K. Anderson, D. A. Price, A. G. Brooks, J. Rossjohn, and D. W. McVicar. 2014. Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity. J. Immunol. 192: 2875-2884.
22. O'Connor, G. M., J. P. Vivian, E. Gostick, P. Pymm, B. A. P. Lafont, D. A. Price, J. Rossjohn, A. G. Brooks, and D. W. McVicar. 2015. Peptide-dependent recognition of HLA-B∗57:01 by KIR3DS1. J. Virol. 89: 5213-5221.
23. O'Connor, G. M., K. J. Guinan, R. T. Cunningham, D. Middleton, P. Parham, and C. M. Gardiner. 2007. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J. Immunol. 178: 235-241.
24. Martin, M. P., Y. Qi, X. Gao, E. Yamada, J. N. Martin, F. Pereyra, S. Colombo, E. E. Brown, W. L. Shupert, J. Phair, et al. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39: 733-740.
25. Cohen, G. B., R. T. Gandhi, D. M. Davis, O. Mandelboim, B. K. Chen, J. L. Strominger, and D. Baltimore. 1999. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10: 661-671.
26. Bonaparte, M. I., and E. Barker. 2004. Killing of human immunodeficiency virus-infected primary T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the expression of major histocompatibility complex class I molecules. Blood 104: 2087-2094.
27. Yawata, M., N. Yawata, M. Draghi, F. Partheniou, A.-M. Little, and P. Parham. 2008. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112: 2369-2380.
28. Kamya, P., S. Boulet, C. M. Tsoukas, J. P. Routy, R. Thomas, P.Côté, M.-R. Boulassel, J.-G. Baril, C. Kovacs, S. A. Migueles, et al; Canadian Cohort of HIV Infected Slow Progressors. 2011. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1∗h/∗y and HLA-B∗57. J. Virol. 85: 5949-5960.
29. Kamya, P., B. Tallon, C. Melendez-Pena, M. S. Parsons, S. A. Migueles, M. Connors, S. Miconiatis, R. Song, S. Boulet, J. Bruneau, et al; investigators of the Canadian Cohort of HIV Infected Slow Progressors. 2012. Inhibitory killer immunoglobulin-like receptors to self HLA-B and HLA-C ligands contribute differentially to natural killer cell functional potential in HIV infected slow progressors. Clin. Immunol. 143: 246-255.
30. Song, R., I. Lisovsky, B. Lebouché, J. P. Routy, J. Bruneau, and N. F. Bernard. 2014. HIV protective KIR3DL1/S1-HLA-B genotypes influence NK cellmediated inhibition of HIV replication in autologous CD4 targets. PLoS Pathog. 10: e1003867.
31. Mulrooney, T. J., A. C. Zhang, Y. Goldgur, J. E. Boudreau, and K. C. Hsu. 2015. KIR3DS1-specific D0 domain polymorphisms disrupt KIR3DL1 surface expression and HLA binding. J. Immunol. 195: 1242-1250.
32. Venstrom, J. M., B. Dupont, K. C. Hsu, G. Pittari, T. A. Gooley, J. H. Chewning, S. Spellman, M. Haagenson, M. M. Gallagher, M. Malkki, and E. Petersdorf. 2014. Donor activating KIR2DS1 in leukemia. N. Engl. J. Med. 371: 2042.
33. Vierra-Green, C., D. Roe, L. Hou, C. K. Hurley, R. Rajalingam, E. Reed, T. Lebedeva, N. Yu, M. Stewart, H. Noreen, et al. 2012. Allele-level haplotype frequencies and pairwise linkage disequilibrium for 14 KIR loci in 506 European-American individuals. PLoS One 7: e47491.
34. Tao, S. D., Y. M. He, Y. L. Ying, J. He, F. M. Zhu, and H. J. Lv. 2014. KIR3DL1 genetic diversity and phenotypic variation in the Chinese Han population. Genes Immun. 15: 8-15.
35. Hilton, H. G., A. K. Moesta, L. A. Guethlein, J. Blokhuis, P. Parham, and P. J. Norman. 2015. The production of KIR-Fc fusion proteins and their use in a multiplex HLA class I binding assay. J. Immunol. Methods 425: 79-87.
36. Cribbs, A. P., A. Kennedy, B. Gregory, and F. M. Brennan. 2013. Simplified production and concentration of lentiviral vectors to achieve high transduction in primary human T cells. BMC Biotechnol. 13: 98.
37. Davis, Z. B., J. P. Ward, and E. Barker. 2011. Preparation and use of HIV-1 infected primary CD4+ T-cells as target cells in natural killer cell cytotoxic assays. J. Vis. Exp. 49: 2668.
38. Gorny, M. K., V. Gianakakos, S. Sharpe, and S. Zolla-Pazner. 1989. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 86: 1624-1628.
39. Tyler, D. S., S. D. Stanley, S. Zolla-Pazner, M. K. Gorny, P. P. Shadduck, A. J. Langlois, T. J. Matthews, D. P. Bolognesi, T. J. Palker, and K. J. Weinhold. 1990. Identification of sites within gp41 that serve as targets for antibodydependent cellular cytotoxicity by using human monoclonal antibodies. J. Immunol. 145: 3276-3282.
40. Robinson, W. E., Jr., M. K. Gorny, J.-Y. Xu, W. M. Mitchell, and S. Zolla-Pazner. 1991. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J. Virol. 65: 4169-4176.
41. Single, R. M., M. P. Martin, X. Gao, D. Meyer, M. Yeager, J. R. Kidd, K. K. Kidd, and M. Carrington. 2007. Global diversity and evidence for coevolution of KIR and HLA. Nat. Genet. 39: 1114-1119.
42. Thomas, R., E. Yamada, G. Alter, M. P. Martin, A. A. Bashirova, P. J. Norman, M. Altfeld, P. Parham, S. K. Anderson, D.W. McVicar, and M. Carrington. 2008. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J. Immunol. 180: 6743-6750.
43. Hilton, H. G., L. Vago, A. M. Older Aguilar, A. K. Moesta, T. Graef, L. Abi-Rached, P. J. Norman, L. A. Guethlein, K. Fleischhauer, and P. Parham. 2012. Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3. J. Immunol. 189: 1418-1430.
44. Pando, M. J., C. M. Gardiner, M. Gleimer, K. L. McQueen, and P. Parham. 2003. The protein made from a common allele of KIR3DL1 (3DL1∗004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1. J. Immunol. 171: 6640-6649.
45. Taner, S. B., M. J. Pando, A. Roberts, J. Schellekens, S. G. Marsh, K. J. Malmberg, P. Parham, and F. M. Brodsky. 2011. Interactions of NK cell receptor KIR3DL1∗004 with chaperones and conformation-specific antibody reveal a functional folded state as well as predominant intracellular retention. J. Immunol. 186: 62-72.
46. Vivian, J. P., R. C. Duncan, R. Berry, G. M. O'Connor, H. H. Reid, T. Beddoe, S. Gras, P. M. Saunders, M. A. Olshina, J. M. Widjaja, et al. 2011. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 479: 401-405.
47. Bird, L. A., C. A. Peh, S. Kollnberger, T. Elliott, A. J. McMichael, and P. Bowness. 2003. Lymphoblastoid cells express HLA-B27 homodimers both intracellularly and at the cell surface following endosomal recycling. Eur. J. Immunol. 33: 748-759.
48. Carrington, M., and G. Alter. 2012. Innate immune control of HIV. Cold Spring Harb. Perspect. Med. 2: a007070.
49. Boulet, S., M. Kleyman, J. Y. Kim, P. Kamya, S. Sharafi, N. Simic, J. Bruneau, J. P. Routy, C. M. Tsoukas, and N. F. Bernard. 2008. A combined genotype of KIR3DL1 high expressing alleles and HLA-B∗57 is associated with a reduced risk of HIV infection. AIDS 22: 1487-1491.
50. Akkina, R. K., R. M. Walton, M. L. Chen, Q. X. Li, V. Planelles, and I. S. Chen. 1996. High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70: 2581-2585.
51. Alter, G., M. P. Martin, N. Teigen, W. H. Carr, T. J. Suscovich, A. Schneidewind, H. Streeck, M. Waring, A. Meier, C. Brander, et al. 2007. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204: 3027-3036.
52. Carrington, M., M. P. Martin, and J. van Bergen. 2008. KIR-HLA intercourse in HIV disease. Trends Microbiol. 16: 620-627.
53. Habegger de Sorrentino, A., J. L. Sinchi, K. Marinic, R. López, and E. Iliovich. 2013. KIR-HLA-A and B alleles of the Bw4 epitope against HIV infection in discordant heterosexual couples in Chaco Argentina. Immunology 140: 273-279.
54. Martin, M. P., X. Gao, J.-H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, K. Hoots, D. Vlahov, J. Trowsdale, et al. 2002. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31: 429-434.
55. Goulder, P. J. R., and B. D. Walker. 2012. HIV and HLA class I: an evolving relationship. Immunity 37: 426-440.
56. Jennes, W., S. Verheyden, J. W. Mertens, M. Camara, M. Seydi, T. N. Dieye, S. Mboup, C. Demanet, and L. Kestens. 2013. Inhibitory KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission. Blood 121: 1157-1164.
57. Hsu, K. C., C. A. Keever-Taylor, A. Wilton, C. Pinto, G. Heller, K. Arkun, R. J. O'Reilly, M. M. Horowitz, and B. Dupont. 2005. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 105: 4878-4884.
58. Hadaya, K., C. de Rham, C. Bandelier, C. Bandelier, S. Ferrari-Lacraz, S. Jendly, T. Berney, L. Buhler, L. Kaiser, J. D. Seebach, et al. 2008. Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am. J. Transplant. 8: 2674-2683.
59. Raulet, D. H., and R. E. Vance. 2006. Self-tolerance of natural killer cells. Nat. Rev. Immunol. 6: 520-531.
60. Yokoyama, W. M., and S. Kim. 2006. How do natural killer cells find self to achieve tolerance? Immunity 24: 249-257.
61. Brodin, P., T. Lakshmikanth, S. Johansson, K. Kärre, and P. Höglund. 2009. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 113: 2434-2441.
62. Brodin, P., T. Lakshmikanth, K. Kärre, and P. Höglund. 2012. Skewing of the NK cell repertoire by MHC class I via quantitatively controlled enrichment and contraction of specific Ly49 subsets. J. Immunol. 188: 2218-2226.
63. Brodin, P., T. Lakshmikanth, R. Mehr, M. H. Johansson, A. D. Duru, A. Achour, M. Salmon-Divon, K. Kärre, P. Höglund, and S. Johansson. 2010. Natural killer cell tolerance persists despite significant reduction of self MHC class I on normal target cells in mice. PLoS One 5: e13174.
64. Joncker, N. T., N. C. Fernandez, E. Treiner, E. Vivier, and D. H. Raulet. 2009. NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model. J. Immunol. 182: 4572-4580.
65. Jonsson, A. H., L. Yang, S. Kim, S. M. Taffner, and W. M. Yokoyama. 2010. Effects of MHC class I alleles on licensing of Ly49A+ NK cells. J. Immunol. 184: 3424-3432.
66. Apps, R., Y. Qi, J. M. Carlson, H. Chen, X. Gao, R. Thomas, Y. Yuki, G. Q. Del Prete, P. Goulder, Z. L. Brumme, et al. 2013. Influence of HLA-C expression level on HIV control. Science 340: 87-91.
67. Kim, S., J. B. Sunwoo, L. Yang, T. Choi, Y.-J. Song, A. R. French, A. Vlahiotis, J. F. Piccirillo, M. Cella, M. Colonna, et al. 2008. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl. Acad. Sci. USA 105: 3053-3058.
68. Kollnberger, S., L. Bird, M. Y. Sun, C. Retiere, V. M. Braud, A. McMichael, and P. Bowness. 2002. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum. 46: 2972-2982.
69. Guia, S., B. N. Jaeger, S. Piatek, S. Mailfert, T. Trombik, A. Fenis, N. Chevrier, T. Walzer, Y. M. Kerdiles, D. Marguet, et al. 2011. Confinement of activating receptors at the plasma membrane controls natural killer cell tolerance. Sci. Signal. 4: ra21.
70. Thomas, L. M., M. E. Peterson, and E. O. Long. 2013. Cutting edge: NK cell licensing modulates adhesion to target cells. J. Immunol. 191: 3981-3985.
71. Jiang, Y., O. Chen, C. Cui, B. Zhao, X. Han, Z. Zhang, J. Liu, J. Xu, Q. Hu, C. Liao, and H. Shang. 2013. KIR3DS1/L1 and HLA-Bw4-80I are associated with HIV disease progression among HIV typical progressors and long-term nonprogressors. BMC Infect. Dis. 13: 405.
72. Elboim, M., I. Grodzovski, E. Djian, D. G. Wolf, and O. Mandelboim. 2013. HSV-2 specifically down regulates HLA-C expression to render HSV-2-infected DCs susceptible to NK cell killing. PLoS Pathog. 9: e1003226.